Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Updated: 11/05/2010) - The drug cabazitaxel improves the survival of some patients with advanced prostate cancer compared with those who receive standard chemotherapy.
Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
(Posted: 06/19/2009, Updated: 11/05/2010) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.
Rituximab Improves Outcomes for Patients With Chronic Lymphocytic Leukemia
(Posted: 01/14/2009, Updated: 11/05/2010) - Advanced chronic lymphocytic leukemia patients who received the monoclonal antibody rituximab in addition to standard chemotherapy with fludarabine and cyclophosphamide (FC) had outcomes far better than those patients who received FC alone, according to studies presented December 2008 at the American Society of Hematology meeting.
Less-Invasive Lymph Node Surgery Safe for Women with Breast Cancer
(Posted: 11/04/2010) - Breast cancer patients who had sentinel lymph node biopsy followed by axillary lymph node dissection (ALND) only if cancer cells were detected in the sentinel nodes had the same overall survival as those who underwent ALND regardless of sentinel node status, according to a randomized trial published online September 20, 2010, in Lancet Oncology.
Lung cancer trial results show mortality benefit with low-dose CT:
(Posted: 11/04/2010) - The NCI has released initial results from a large-scale test of screening methods to reduce deaths from lung cancer by detecting cancers at relatively early stages. The National Lung Screening Trial, a randomized national trial involving more than 53,000 current and former heavy smokers ages 55 to 74, compared the effects of two screening procedures for lung cancer -- low-dose helical computed tomography (CT) and standard chest X-ray -- on lung cancer mortality and found 20 percent fewer lung cancer deaths among trial participants screened with low-dose helical CT.